Cancers, Vol. 13, Pages 5899: Neo-Adjuvant Chemotherapy Reduces, and Surgery Increases Immunosuppression in First-Line Treatment for Ovarian Cancer

Conclusion: The implementation of immunotherapy in the primary treatment schedule of ovarian cancer cannot be induced blindly. Carboplatin–paclitaxel seems to ameliorate the hostile immune microenvironment in ovarian cancer, which is less pronounced at the end of primary treatment. This prospective study during primary therapy for ovarian cancer that also looks at the evolution of immune-related proteins provides us with an insight into the temporary windows of opportunity in which to introduce immunotherapy during primary treatment.

Source: Cancers - November 24, 2021 Category: Cancer & Oncology Authors: Christine De Bruyn Jolien Ceusters Chiara Landolfo Tha ïs Baert Gitte Thirion Sandra Claes Ann Vankerckhoven Roxanne Wouters Dominique Schols Dirk Timmerman Ignace Vergote An Coosemans Tags: Article Source Type: research